Posts

Affinity and receptor expression limits tested for LRC-TriCEPS

Dualsystems Biotech AG is testing the limits of the LRC-TriCEPSTM (CaptiRec) technology using antibodies with different affinities against the same target and cells expressing the target receptor with different expression levels.

Limits-of-LRC-TriCEPS

Limits-of-LRC-TriCEPS

Details of the assesment see here

Dualsystems Biotech AG and Biaffin GmbH & Co KG perform together an example of an experiment

Dualsystems Biotech AG and Biaffin GmbH & Co KG  perform together an example of an experiment.

In the case study Dualsystems Biotech AG determined the targets of the Anti EGFR antibodies and Biaffin GmbH& Co KG  measured the binding characteristics of the ligand receptor interaction using Surface Plasmon Resonance (SPR).

 

Video – how the LRC-TriCEPS™ technology works

Dualsystems Biotech AG Press Release

How the LRC-TriCEPS™ technology works (Video)

Zürich Switzerland – June 23, 2014 – Dualsystems Biotech AG offers the most advanced technology for identifying receptor(s) for orphan ligands. The ligand-receptor capture technology (LRC-TriCEPS™) is an innovative and conceptually new approach for the unbiased discovery of cell surface interactions of ligands ranging from peptides, proteins, antibodies to viruses. Dualsystems offers the LRC-TriCEPS™ technology in our service line CaptiRec. We offer a variety of formats which will fit your needs: From CaptiRec Kits for your own in-house experiments to an all-inclusive CaptiRec Service.

Dualsystems Biotech AG is looking forward to support your project with the newest invention in receptor/target discovery.

Please watch the video where we explain how the LRC-TriCEPS™ technology works: LRC-TriCEPS™-Video